Teva Pharmaceutical Industries says that it has been given the green light by regulators in the USA to sell its generic version of AstraZeneca’s cancer blockbuster Arimidex.
The Israeli company has received US Food and Drug Administration approval and commercial launch for its copycat version of Arimidex (anastrozole) which is indicated for the treatment of certain forms of breast cancer in postmenopausal women. The...
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Ceplene® (histamine dihydrochloride). EpiCept is seeking approval for Ceplene, administered concomitantly with low-dose interleukin-2 (IL-2), for the remission...
June 28, 2010 01:00 PM Eastern Daylight Time
Research and Markets: Formulary Advantages in Orally Delivered Oncology Agents: Impact of Cost Controls and Emerging Agents on Key Brands
Source: Tarix Pharmaceuticals
Tarix Pharmaceuticals' TXA127 Receives FDA Orphan Drug Designation For Stem Cell Engraftment
Tarix Pharmaceuticals announced that it's drug, TXA127, has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) as a treatment to enhance engraftment in patients receiving a stem cell transplant. TXA127 has also received Orphan Drug designation for the treatment of Myelodysplastic Syndrome (MDS).
CENTENNIAL, Colo.--(BUSINESS WIRE)--Cell>Point announced today that it has closed the Phase 2 portion of its Phase 2/3 trial of 99mTc-EC-G in evaluating patients with non-small cell lung cancer (NSCLC).
The Phase 2/3 clinical trial compares the efficacy and safety of 99mTc-EC-G administered and then imaged with a SPECT /CT camera to 18F-FDG administered and then imaged with a PET/CT camera in the evaluation of patients...
Blog Categories
Uncategorized
(5)
